Lenacapavir - Generic Drug Details
✉ Email this page to a colleague
Anatomical Therapeutic Chemical (ATC) Classes for Lenacapavir
US Patents and Regulatory Information for Lenacapavir
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | YEZTUGO | lenacapavir sodium | TABLET;ORAL | 220020-001 | Jun 18, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Gilead Sciences Inc | YEZTUGO | lenacapavir sodium | TABLET;ORAL | 220020-001 | Jun 18, 2025 | RX | Yes | Yes | 11,267,799 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Gilead Sciences Inc | YEZTUGO | lenacapavir sodium | SOLUTION;SUBCUTANEOUS | 220018-001 | Jun 18, 2025 | RX | Yes | Yes | 11,267,799 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Gilead Sciences Inc | SUNLENCA | lenacapavir sodium | SOLUTION;SUBCUTANEOUS | 215973-001 | Dec 22, 2022 | RX | Yes | Yes | 9,951,043 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
